My takeaways from the webinar:
Confirmation that other neuro indications are still strongly being looked at, even if there has not been much newsflow in that area for a while.FDA's timeline for responding to our re-submission after current clinical hold is 30 days
9 month readout is still planned for the Healy trial, after which if the endpoints have been met they can elect to apply for drug approval straightaway.
NT Trader's real name is actually "New Zealand Trader"
CFO was giving pretty cagey answers about next funding initiatives, and did not mention "non-dilutive finding" yet he gave strong indications that any CR would be a long way off and it is likely that current holders' interests would be protected as much as possible.
MT and CFO both seemed bullish on the viability of the options, on account of the price-sensitive events due to take place between now and expiry.
(20min delay)